top of page
CONSEQTIVE
LEADERSHIP
Marc Siladi
Partner, ConseQtive
Science-to-Commercialization Leadership:
Life sciences executive with a track record of taking scientific innovation from discovery through commercialization. His experience spans protein biochemistry, biologics, laboratory automation, digital health, and pharmaceutical operations.
Proven Value Creation:
Leads business strategy, operations, and market expansion at Koneksa Health. Former Chief Operating Officer of Strateos, where he led the development and commercialization of the world’s first robotic cloud laboratory, culminating in a successful exit.
Big Pharma & Industry Depth
Senior roles at Gilead Sciences, Thermo Fisher Scientific, and Vertex Pharmaceuticals. At Gilead, he applied AI-driven logistics to optimize the supply chain for Remdesivir, the first FDA-approved COVID-19 treatment. At Vertex, as a protein biochemist, he contributed to foundational advances in cystic fibrosis therapies targeting the genetic root of the disease.
General of ConseQtive:
Brings proven, creative operating experience to companies ranging from startups to the S&P 500. His focus areas include turnarounds, sales and market development, fractional CEO and COO leadership, and product and software development. Companies engage ConseQtive to build from scratch, to rebuild, and to lead turnarounds.
Scientific & Technical Acumen:
BS in Biochemistry from UC San Diego and graduate studies in Mathematics at Penn State. Inventor on seven patents spanning biologics, protein engineering, and nanotechnology, and author of multiple scientific publications.
Advisory Roles
Serves on the scientific advisory boards of several emerging life sciences companies, contributing technical depth on platform, product, and commercialization decisions.
Leadership Philosophy:
Passionate about advancing science, building high-performing teams, solving complex business and technology challenges, and creating sustainable value for companies, investors, customers, and stakeholders.
bottom of page